Log in to save to my catalogue

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting...

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c546c4aa8ad646f0bacb45d5ad1bc555

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System

About this item

Full title

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System

Publisher

United States: John Wiley & Sons, Inc

Journal title

The journal of clinical hypertension (Greenwich, Conn.), 2025-03, Vol.27 (3), p.e70029-n/a

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

ABSTRACT
Hypertension exerts a significant global disease burden, adversely affecting the well‐being of billions. Alarmingly, drug‐related hypertension remains an area that has not been comprehensively investigated. Therefore, this study is designed to utilize the adverse event reports (AERs) from the US Food and Drug Administration's Adverse Ev...

Alternative Titles

Full title

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c546c4aa8ad646f0bacb45d5ad1bc555

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c546c4aa8ad646f0bacb45d5ad1bc555

Other Identifiers

ISSN

1524-6175,1751-7176

E-ISSN

1751-7176

DOI

10.1111/jch.70029

How to access this item